Seres Therapeutics To Host July 8 Webcast To Discuss Top-Line Results From A Trial Evaluating SER-155 In Patients With Immune Checkpoint Inhibitor-Related Enterocolitis
Benzinga Newsdesk 4 months ago
News
The IST was conducted at Memorial Sloan Kettering Cancer Center, with which Seres has a long history of collaboration, by Principal Investigator David Faleck, M.D., Director of Inflammatory and Immune-Related Bowel
The IST was conducted at Memorial Sloan Kettering Cancer Center, with which Seres has a long history of collaboration, by Principal Investigator David Faleck, M.D., Director of Inflammatory and Immune-Related Bowel Diseases. The webcast will occur on July 8, 2026, at 8:30 am ET.
To access the conference call, please dial 800-715-9871 (domestic) or 646-307-1963 (international) and reference the conference ID number 3327556. To join the live webcast, please visit the "Events and Presentations" tab within the "Investors and News" section of the Seres website at www.serestherapeutics.com. The webcast will be available for replay following the event.